Status:
COMPLETED
Desensitization of Renal Transplant Candidates
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Novartis
Conditions:
End Stage Renal Disease
Kidney Transplantation
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation.
Detailed Description
Pre-formed HLA antibodies prevent renal transplantation because of the risk of hyperacute rejection. We propose a prospective study evaluating the efficacy of Enteric Coated Mycophenolate Sodium (Myfo...
Eligibility Criteria
Inclusion
- Patients on the deceased donor kidney transplant waiting list with panel reactive antibodies \>50% and living donor waiting list patients who have a history of a positive crossmatch (donor-specific antibodies) will be eligible for the study.
Exclusion
- Any subjects not meeting the Inclusion Criteria
- Subjects unable to attend weekly clinic visits for six weeks
- Inability to tolerate Myfortic
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00298883
Start Date
February 1 2006
End Date
December 1 2008
Last Update
July 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610